Business Context and Reporting Period
This Form 8-K reports on a special meeting of stockholders held by AlloVir, Inc. (not Kalaris Therapeutics, Inc., despite the metadata request) on January 9, 2025. The filing details the results of a vote regarding a proposed reverse stock split, which is a precursor to a proposed merger between AlloVir and Kalaris Therapeutics, Inc.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, data on revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Voting Results
At the special meeting, stockholders representing approximately 93.97% of the voting power (108,601,328 votes) were present, constituting a quorum. The following material actions were taken:
- Proposal 1 (Reverse Stock Split): Stockholders approved an amendment to the Charter authorizing a reverse stock split. The Board of Directors may now effect a split at any time prior to January 10, 2026, at a ratio between 1-for-15 and 1-for-35. The exact ratio will be determined by the Board without further shareholder approval.
- Voting Breakdown for Proposal 1:
- Votes For: 96,216,120
- Votes Against: 12,082,172
- Votes Abstaining: 303,036
- Proposal 2 (Adjournment): This proposal was not called for a vote because sufficient votes were cast to approve the Reverse Stock Split Proposal.
Guidance, Outlook, and Risks
Outlook and Timing: The timing and specific ratio of the reverse stock split will be determined by the Board and announced publicly once decided. The filing explicitly states this action is in connection with the proposed merger between AlloVir and Kalaris Therapeutics, Inc.
Risks and Contingencies: The filing includes standard disclaimers that this communication is not an offer to buy or sell securities. Investors are urged to read the Form S-4 and Proxy Statements for complete information regarding the merger and reverse stock split risks.
Important Facts for Investors to Verify
- Confirm the exact reverse stock split ratio and implementation date once announced by the Board.
- Review the Form S-4 and Proxy Statements for details on the proposed merger between AlloVir and Kalaris Therapeutics, Inc.
- Note that the registrant in this filing is AlloVir, Inc. (Ticker: ALVR), not Kalaris Therapeutics, Inc.
- Verify the impact of the reverse stock split on existing holdings and the potential for fractional shares.